Washington, D.C. 20549 
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2020
(Exact name of registrant as specified in its charter)

Delaware 000-30713 77-0416458
(State or other jurisdiction
of incorporation)
File Number)
 (I.R.S. Employer
Identification No.)
1020 Kifer Road
Sunnyvale, California 94086
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (408523-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨  

Item 2.02.
Results of Operations and Financial Condition.
On April 16, 2020, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended March 31, 2020. A copy of the press release is furnished hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01.
Financial Statements and Exhibits.
d) Exhibits.
Exhibit No.Description
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 16, 2020 By:/s/ Marshall L. Mohr
     Name: Marshall L. Mohr
     Title: Executive Vice President and Chief Financial Officer

EX-99.1 2 a20200331ex-991.htm EX-99.1 Document

Exhibit 99.1

Contact: Investor Relations
(408) 523-2161
SUNNYVALE, CALIF. April 16, 2020 – Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2020. Procedure volume and systems placements in the quarter are consistent with the preliminary results disclosed in the Company's press release on April 8, 2020.
Q1 Highlights
Worldwide da Vinci procedures grew approximately 10% compared with the first quarter of 2019, driven primarily by growth in U.S. general surgery procedures and worldwide urologic procedures.
The Company shipped 237 da Vinci Surgical Systems, an increase of 1% compared with 235 in the first quarter of 2019.
The Company grew its da Vinci Surgical System installed base to 5,669 systems as of March 31, 2020, an increase of 11% compared with 5,114 as of the end of the first quarter of 2019.
First quarter 2020 revenue of $1,100 million grew 13% compared with $974 million in the first quarter of 2019.
First quarter 2020 GAAP net income was $314 million, or $2.62 per diluted share, compared with $307 million, or $2.56 per diluted share, in the first quarter of 2019.
First quarter 2020 non-GAAP* net income was $323 million, or $2.69 per diluted share, compared with $312 million, or $2.61 per diluted share, in the first quarter of 2019.
In February 2020, the Company acquired Orpheus Medical Ltd. and its wholly owned subsidiaries (“Orpheus Medical”) to deepen and expand its integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical videos.
Q1 Financial Summary
Gross profit, income from operations, net income, net income per diluted share, and diluted shares are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.
First quarter 2020 revenue was $1,100 million, an increase of 13% compared with $974 million in the first quarter of 2019. Higher first quarter revenue was driven by increased procedures and systems placements as well as higher service and operating lease revenue.
First quarter 2020 instruments and accessories revenue increased by 12% to $618 million, compared with $552 million in the first quarter of 2019, primarily driven by approximately 10% growth in da Vinci procedure volume.
First quarter 2020 systems revenue increased by 14% to $283 million, compared with $248 million in the first quarter of 2019. The Company shipped 237 da Vinci Surgical Systems in the first quarter of 2020, compared with 235 in the first quarter of 2019. The first quarter 2020 system shipments included 77 systems shipped under operating lease and usage-based arrangements, compared with 78 in the first quarter of 2019.
First quarter 2020 GAAP income from operations increased to $283 million, compared with $252 million in the first quarter of 2019. First quarter 2020 GAAP income from operations included intangible asset charges of $13 million, compared with $30 million in the first quarter of 2019, and share-based compensation expense of $91 million, compared with $76 million in the first quarter of 2019. First quarter 2020 non-GAAP* income from operations increased to $384 million, compared with $362 million in the first quarter of 2019.
First quarter 2020 GAAP net income was $314 million, or $2.62 per diluted share, compared with $307 million, or $2.56 per diluted share, in the first quarter of 2019. First quarter 2020 GAAP net income included excess tax benefits of $65 million, or $0.55 per share, compared with $73 million, or $0.61 per share, in the first quarter of 2019.
First quarter 2020 non-GAAP* net income was $323 million, or $2.69 per diluted share, compared with $312 million, or $2.61 per diluted share, in the first quarter of 2019.
Page 1 of 7

The Company ended the first quarter of 2020 with $5.9 billion in cash, cash equivalents, and investments, an increase of $51 million during the quarter, primarily driven by cash generated from operations.
Impact of COVID-19 Pandemic
For the first two and a half months of the first quarter of 2020, procedure performance was trending at the higher end of our expectations. However, as noted in the Company's April 8 press release, the Company experienced a significant decline in procedure volume and postponements of system placements in the latter half of March in the U.S. and Western Europe, as healthcare systems in those areas diverted resources to meet the increasing demands of managing COVID-19. The Company has experienced and believes that the impact of the COVID-19 pandemic on the Company's business differs by geography. Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, we cannot, at this time, reliably estimate the future impact on our operations and financial results.
“In response to COVID-19, Intuitive's priorities are the health and safety of those we serve, including care teams, their patients, our employees, our communities, and our suppliers," said Intuitive CEO Gary Guthart. “While we cannot predict the depth or duration of the disruption caused by the pandemic, we remain committed to our mission and the long-term need to improve patient outcomes.”
Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at https://isrg.gcs-web.com/.
Webcast and Conference Call Information
Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the first quarter 2020 financial results. The call will be webcast by Nasdaq OMX and can be accessed on Intuitive’s website at www.intuitive.com or by dialing (877) 226-8163 using the access code 8991765.
About Intuitive
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. At Intuitive, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.
Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings and develops, manufactures, and markets the da Vinci Surgical System and the Ion endoluminal system.
Da Vinci® and IonTM are trademarks or registered trademarks of Intuitive Surgical, Inc.
For more information, please visit the Company’s website at www.intuitive.com.
Page 2 of 7

Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are necessarily estimates reflecting the best judgment of the Company's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to the potential impacts of the COVID-19 pandemic on our business, financial condition and results of operations, the strength of our long-term fundamentals, the potential decline of procedure volume, our acquisitions, expected new product introductions, procedures and procedure adoption, future results of operations, future financial position, our ability to increase our revenues, the anticipated mix of our revenues between product and service revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, our potential tax assets or liabilities, the effect of recent accounting pronouncements, our investments, anticipated cash flows, our ability to finance operations from cash flows and similar matters, and statements based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and our beliefs and assumptions regarding these economies and markets. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the ability of the Company to obtain accurate procedure volume in the midst of the COVID-19 pandemic, the risk that the COVID-19 pandemic could lead to further material delays and cancellations of procedures, curtailed or delayed capital spending by hospitals and disruption to our supply chain, closures of our facilities, delays in surgeon training, delays in gathering clinical evidence, or diversion of management and other resources to respond to the COVID-19 pandemic; the evaluation of the risks of robotic-assisted surgery in the presence of infectious diseases, the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic disrupts local economies and causes economies in our key markets to enter prolonged recessions; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company's completion of and ability to successfully integrate the acquisitions, including Schölly Fiberoptic's robotic endoscope business and Orpheus Medical; procedure counts; regulatory approvals, clearances, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which the Company operates; risks associated with our operations outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company's reliance on sole and single source suppliers; disruptions in operations from medical epidemics or pandemics, such as COVID-19, and other natural or manmade disasters or catastrophic events; the results of legal proceedings to which the Company is or may become a party; product liability and other litigation claims; adverse publicity regarding us and the safety of the Company's products and adequacy of training; the Company's ability to expand into foreign markets; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by the Company’s other filings with the Securities and Exchange Commission. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Page 3 of 7

*About Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, non-GAAP net income per diluted share (“EPS”), and non-GAAP diluted shares. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding items such as intangible asset charges, share-based compensation (“SBC”) expenses, and other special items. Intangible asset charges consist of non-cash charges, such as the amortization of intangible assets, as well as in-process R&D charges. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.
Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit, excluding intangible asset charges, expenses related to SBC, and litigation charges and recoveries.
Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations, excluding intangible asset charges, certain acquisition-related items for the re-measurement of contingent consideration, expenses related to SBC, and litigation charges and recoveries.
Non-GAAP net income and EPS. The Company defines non-GAAP net income as net income (loss), excluding intangible asset charges, non-cash impairment charges and recoveries, certain acquisition-related items for the re-measurement of contingent consideration, expenses related to SBC, litigation charges and recoveries, adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects, and tax adjustments, including the excess tax benefits or deficiencies associated with SBC arrangements, the one-time impact of the enactment of the 2019 Swiss tax reform, and the net tax effects related to intra-entity transfers of non-inventory assets. The Company excludes the one-time impact of the enactment of the 2019 Swiss tax reform, because it is discrete in nature, and excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the on-going results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income divided by non-GAAP diluted shares, which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.
There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, and non-GAAP EPS exclude items such as intangible asset charges, re-measurement of contingent consideration, SBC, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. SBC has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income and non-GAAP EPS and evaluating non-GAAP net income and non-GAAP EPS together with net income (loss) and net income (loss) per share calculated in accordance with GAAP.

Page 4 of 7

Three months ended
March 31,
December 31,
March 31,
Instruments and accessories$617.5  $671.2  $552.3  
Systems283.3  416.2  247.5  
Services198.7  190.3  173.9  
Total revenue1,099.5  1,277.7  973.7  
Cost of revenue:
Product296.7  312.0  246.4  
Service64.6  69.7  57.7  
Total cost of revenue361.3  381.7  304.1  
Gross profit738.2  896.0  669.6  
Operating expenses:
Selling, general and administrative308.1  341.8  273.4  
Research and development147.1  156.6  144.0  
Total operating expenses455.2  498.4  417.4  
Income from operations (1)283.0  397.6  252.2  
Interest and other income, net25.1  34.1  27.5  
Income before taxes308.1  431.7  279.7  
Income tax expense (benefit) (2)(8.1) 69.0  (24.3) 
Net income316.2  362.7  304.0  
Less: net income (loss) attributable to noncontrolling interest in joint venture2.7  5.0  (2.5) 
Net income attributable to Intuitive Surgical, Inc.$313.5  $357.7  $306.5  
Net income per share attributable to Intuitive Surgical, Inc.:
Basic $2.69  $3.09  $2.67  
Diluted (3)$2.62  $2.99  $2.56  
Weighted average shares outstanding:
Basic116.4  115.8  115.0  
Diluted119.8  119.7  119.6  
(1) Income from operations includes the effect of the following item:
Intangible asset charges$13.3  $15.7  $30.2  
(2) Income tax expense (benefit) includes the effect of the following item:
Excess tax benefits related to share-based compensation arrangements$(65.4) $(33.7) $(72.7) 
(3) Diluted net income per share includes the effect of the following items:
Intangible asset charges, net of tax$(0.10) $(0.11) $(0.21) 
Excess tax benefits related to share-based compensation arrangements$0.55  $0.28  $0.61  

Page 5 of 7

March 31,
December 31,
Cash, cash equivalents, and investments$5,896.1  $5,845.2  
Accounts receivable, net527.6  645.2  
Inventory620.3  595.5  
Property, plant, and equipment, net1,369.2  1,272.9  
Goodwill335.0  307.2  
Deferred tax assets364.7  425.6  
Other assets778.2  641.6  
Total assets$9,891.1  $9,733.2  
Accounts payable and other accrued liabilities$994.4  $1,083.3  
Deferred revenue366.2  365.2  
Total liabilities1,360.6  1,448.5  
Stockholders’ equity8,530.5  8,284.7  
Total liabilities and stockholders’ equity$9,891.1  $9,733.2  

Page 6 of 7

Three months ended
March 31,
December 31,
March 31,
GAAP gross profit$738.2  $896.0  $669.6  
Share-based compensation expense18.0  17.1  15.1  
Intangible asset charges9.7  9.5  8.2  
Non-GAAP gross profit$765.9  $922.6  $692.9  
GAAP income from operations$283.0  $397.6  $252.2  
Share-based compensation expense90.6  89.2  76.1  
Intangible asset charges13.3  15.7  30.2  
Litigation recoveries(1.2) —  —  
Acquisition-related items(1.4) 3.1  3.0  
Non-GAAP income from operations$384.3  $505.6  $361.5  
GAAP net income attributable to Intuitive Surgical, Inc.$313.5  $357.7  $306.5  
Share-based compensation expense90.6  89.2  76.1  
Intangible asset charges13.3  15.7  30.2  
Litigation recoveries(1.2) —  —  
Impairment charges—  —  1.5  
Acquisition-related items(1.4) 3.1  3.0  
Tax adjustments (1)(90.0) (44.9) (101.5) 
Adjustments attributable to noncontrolling interest in joint venture(2.0) (3.8) (3.8) 
Non-GAAP net income attributable to Intuitive Surgical, Inc.$322.8  $417.0  $312.0  
GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted$2.62  $2.99  $2.56  
Share-based compensation expense0.76  0.75  0.64  
Intangible asset charges0.11  0.13  0.25  
Litigation recoveries(0.01) —  —  
Impairment charges—  —  0.01  
Acquisition-related items(0.01) 0.02  0.03  
Tax adjustments (1)(0.76) (0.38) (0.85) 
Adjustments attributable to noncontrolling interest in joint venture(0.02) (0.03) (0.03) 
Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted$2.69  $3.48  $2.61  
(1) For the three months ended March 31, 2020, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(65.4) million, or $(0.55) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $11.3 million, or $0.09 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(35.9) million, or $(0.30) per diluted share.

Page 7 of 7

EX-101.SCH 3 isrg-20200416.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 isrg-20200416_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 isrg-20200416_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 isrg-20200416_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 isrg-20200416_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 11 0001035267-20-000073-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001035267-20-000073-xbrl.zip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htm IDEA: XBRL DOCUMENT v3.20.1
Apr. 16, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 16, 2020
Entity Registrant Name INTUITIVE SURGICAL, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-30713
Entity Tax Identification Number 77-0416458
Entity Address, Address Line One 1020 Kifer Road
Entity Address, City or Town Sunnyvale
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94086
City Area Code 408
Local Phone Number 523-2100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ISRG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001035267
Amendment Flag false
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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isrg-20200416_htm.xml IDEA: XBRL DOCUMENT 0001035267 2020-04-16 2020-04-16 0001035267 false 8-K 2020-04-16 INTUITIVE SURGICAL, INC. DE 000-30713 77-0416458 1020 Kifer Road Sunnyvale CA 94086 408 523-2100 false false false false Common Stock, par value $0.001 per share ISRG NASDAQ false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "isrg-20200416.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "isrg-20200416_cal.xml" ] }, "definitionLink": { "local": [ "isrg-20200416_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "isrg-20200416.htm" ] }, "labelLink": { "local": [ "isrg-20200416_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "isrg-20200416_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "isrg-20200416.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "isrg", "nsuri": "http://www.intuitivesurgical.com/20200416", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "isrg-20200416.htm", "contextRef": "ia0eb4e8dec28492f8a85d19ec9183511_D20200416-20200416", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.intuitivesurgical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "isrg-20200416.htm", "contextRef": "ia0eb4e8dec28492f8a85d19ec9183511_D20200416-20200416", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intuitivesurgical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.intuitivesurgical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports isrg-20200416.htm a20200331ex-991.htm isrg-20200416.xsd isrg-20200416_cal.xml isrg-20200416_def.xml isrg-20200416_lab.xml isrg-20200416_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true